Cyanopyridine derivative and use thereof as medicine
申请人:Morioka Masahiko
公开号:US20090292121A1
公开(公告)日:2009-11-26
A therapeutic drug for cancer containing a substance selected from the group consisting of a novel cyanopyridine derivative, a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate as an active ingredient can be provided.
CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE
申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP1876178B1
公开(公告)日:2015-05-27
US7928126B2
申请人:——
公开号:US7928126B2
公开(公告)日:2011-04-19
The Guareschi Pyridine Scaffold as a Valuable Platform for the Identification of Selective PI3K Inhibitors
作者:Ubaldina Galli、Elisa Ciraolo、Alberto Massarotti、Jean Margaria、Giovanni Sorba、Emilio Hirsch、Gian Tron
DOI:10.3390/molecules200917275
日期:——
A novel series of 4-aryl-3-cyano-2-(3-hydroxyphenyl)-6-morpholino-pyridines have been designed as potential phosphatidylinositol-3-kinase (PI3K) inhibitors. The compounds have been synthesized using the Guareschi reaction to prepare the key 4-aryl-3-cyano-2,6-dihydroxypyridine intermediate. A different selectivity according to the nature of the aryl group has been observed. Compound 9b is a selective inhibitor against the PI3Kα isoform, maintaining a good inhibitory activity. Docking studies were also performed in order to rationalize its profile of selectivity.